Intelligent Bio Solutions Announces Preliminary Fiscal Fourth Quarter Revenue with Double-Digit Sequential and Year-Over-Year Growth and Strong Operational Momentum
Intelligent Bio Solutions (Nasdaq: INBS) announced preliminary fiscal Q4 2025 results, highlighting 16% revenue growth both sequentially and year-over-year. The growth was driven by increased higher-margin cartridge sales and steady account expansion.
The company made significant operational progress, including submitting an FDA 510(k) application for its opiate test system for codeine. INBS also completed multilingual upgrades to its Intelligent Fingerprinting Drug Screening System and launched localized websites with enhanced CRM workflows across Europe, the Middle East, and Latin America.
Final audited results will be disclosed in the Annual Report on Form 10-K, expected during the week of August 11, 2025.
Intelligent Bio Solutions (Nasdaq: INBS) ha annunciato i risultati preliminari del quarto trimestre fiscale 2025, evidenziando una crescita del fatturato del 16% sia rispetto al trimestre precedente che all'anno precedente. La crescita è stata trainata da un aumento delle vendite di cartucce a margine più elevato e da un'espansione costante dei clienti.
L'azienda ha fatto progressi significativi a livello operativo, tra cui la presentazione di una domanda FDA 510(k) per il suo sistema di test per oppiacei specifico per la codeina. INBS ha inoltre completato aggiornamenti multilingue al suo Sistema di Screening Droghe Intelligent Fingerprinting e ha lanciato siti web localizzati con flussi di lavoro CRM migliorati in Europa, Medio Oriente e America Latina.
I risultati finali, revisionati, saranno comunicati nel Rapporto Annuale sul Modulo 10-K, previsto per la settimana dell'11 agosto 2025.
Intelligent Bio Solutions (Nasdaq: INBS) anunció resultados preliminares del cuarto trimestre fiscal de 2025, destacando un crecimiento de ingresos del 16% tanto secuencialmente como en comparación con el año anterior. El crecimiento fue impulsado por un aumento en las ventas de cartuchos de mayor margen y una expansión constante de cuentas.
La compañía logró avances operativos significativos, incluyendo la presentación de una solicitud FDA 510(k) para su sistema de prueba de opiáceos para codeína. INBS también completó actualizaciones multilingües en su Sistema de Detección de Drogas Intelligent Fingerprinting y lanzó sitios web localizados con flujos de trabajo CRM mejorados en Europa, Medio Oriente y América Latina.
Los resultados finales auditados se divulgarán en el Informe Anual en el Formulario 10-K, previsto para la semana del 11 de agosto de 2025.
Intelligent Bio Solutions (나스닥: INBS)는 2025 회계연도 4분기 잠정 실적을 발표하며 전분기 및 전년 대비 16% 매출 성장을 기록했다고 밝혔습니다. 이 성장은 고마진 카트리지 판매 증가와 안정적인 고객 확장에 힘입은 것입니다.
회사는 코드인(opiate) 테스트 시스템에 대한 FDA 510(k) 신청서 제출 등 중요한 운영 진전을 이루었으며, Intelligent Fingerprinting 약물 검사 시스템의 다국어 업그레이드를 완료하고 유럽, 중동, 라틴 아메리카 지역에서 향상된 CRM 워크플로우를 갖춘 현지화된 웹사이트를 출시했습니다.
최종 감사 결과는 2025년 8월 11일 주간에 예정된 Form 10-K 연례 보고서에서 공개될 예정입니다.
Intelligent Bio Solutions (Nasdaq : INBS) a annoncé les résultats préliminaires du quatrième trimestre fiscal 2025, soulignant une croissance des revenus de 16% à la fois séquentiellement et en glissement annuel. Cette croissance a été portée par une augmentation des ventes de cartouches à marge plus élevée et une expansion régulière des comptes.
L'entreprise a réalisé des progrès opérationnels significatifs, notamment en soumettant une demande FDA 510(k) pour son système de test des opiacés pour la codéine. INBS a également achevé des mises à niveau multilingues de son système de dépistage de drogues Intelligent Fingerprinting et a lancé des sites web localisés avec des flux de travail CRM améliorés en Europe, au Moyen-Orient et en Amérique latine.
Les résultats finaux audités seront publiés dans le rapport annuel sur le formulaire 10-K, attendu pour la semaine du 11 août 2025.
Intelligent Bio Solutions (Nasdaq: INBS) gab vorläufige Ergebnisse für das Geschäftsjahr 4. Quartal 2025 bekannt und hob ein Umsatzwachstum von 16% sowohl im Vergleich zum Vorquartal als auch zum Vorjahr hervor. Das Wachstum wurde durch gestiegene Verkäufe von höhermargigen Kartuschen und eine stetige Kontoerweiterung angetrieben.
Das Unternehmen erzielte bedeutende operative Fortschritte, darunter die Einreichung eines FDA 510(k)-Antrags für sein Opiat-Testsystem für Codein. INBS schloss zudem mehrsprachige Upgrades seines Intelligent Fingerprinting Drug Screening Systems ab und startete lokalisierte Websites mit verbesserten CRM-Workflows in Europa, dem Nahen Osten und Lateinamerika.
Die endgültigen geprüften Ergebnisse werden im Jahresbericht auf Formular 10-K veröffentlicht, der in der Woche vom 11. August 2025 erwartet wird.
- Revenue growth of 16% both sequentially and year-over-year
- Expansion of higher-margin cartridge sales
- FDA 510(k) application submitted for opiate test system
- Enhanced global presence through multilingual system upgrades and localization
- Financial results are preliminary and subject to adjustments
- Full financial metrics and profitability details not yet disclosed
Insights
INBS reports 16% revenue growth with regulatory progress and operational scaling, strengthening commercial position despite awaiting final financial details.
Intelligent Bio Solutions has announced preliminary Q4 fiscal 2025 revenue growth of approximately
What's particularly encouraging is that this marks multiple consecutive quarters of sequential growth, suggesting sustainable momentum rather than one-time revenue spikes. The company's focus on cartridge sales is strategically sound, as consumables typically generate higher margins and create a predictable revenue stream compared to one-time device sales.
Beyond financial metrics, INBS has made significant operational progress by submitting its FDA 510(k) application for opiate testing, specifically for codeine detection. FDA clearance would unlock the massive U.S. healthcare and workplace testing markets, potentially accelerating growth substantially. The company is simultaneously scaling globally through system localization and multilingual capabilities – critical steps for penetrating diverse international markets.
While these preliminary results are promising, investors should note they remain subject to adjustment pending the full financial close process. The upcoming 10-K filing expected the week of August 11th will provide essential context including gross margins, operating expenses, cash position, and comprehensive financial guidance that will better illustrate the company's overall financial health and sustainability.
Company anticipates fiscal fourth quarter sequential and year-on-year revenue growth of approximately
Company advanced efforts to secure U.S. FDA 510(k) clearance for planned U.S. market entry and strengthened global readiness through system upgrades and localization
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary, unaudited revenue results and key operational highlights for the fiscal fourth quarter and full-year ended June 30, 2025.
"Fiscal 2025 represented a year of disciplined execution and strategic investment. For the fiscal fourth quarter, we expect to report another quarter of sequential and year-over-year revenue growth." said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "In addition to our strong revenue performance, during the quarter we also made significant progress on the regulatory pathway in seeking U.S. FDA 510(k) clearance and continued scaling our operations globally with system upgrades and localization."
The Company expects to report fiscal fourth quarter 2025 revenue increases of approximately
Operational Highlights
- Submitted FDA 510(k) application for its opiate test system for codeine, supported by new scientific and clinical validation data.
- Completed multilingual upgrades to the Intelligent Fingerprinting Drug Screening System, supporting broader global adoption.
- Launched localized websites and enhanced CRM workflows to improve partner and end-user engagement across Europe, the Middle East, and Latin America.
The preliminary unaudited revenue results for the fiscal fourth quarter and full year ended June 30, 2025, are based on information available to management as of the date of this press release and are, therefore, subject to adjustments based on the Company’s completion of its year-end financial close process. The Company expects to disclose financial results for the fiscal fourth quarter and fiscal year ended June 30, 2025, in its upcoming Annual Report on Form 10-K, expected to be filed with the Securities and Exchange Commission during the week commencing August 11, 2025.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.
For more information, visit https://ibs.inc/
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Investor & Media Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
FAQ
What was INBS's revenue growth in Q4 2025?
What regulatory progress has Intelligent Bio Solutions made for US market entry?
What operational improvements did INBS implement in Q4 2025?
When will Intelligent Bio Solutions release its full fiscal 2025 financial results?
What drove INBS's revenue growth in Q4 2025?
